SCN1A testing for epilepsy: application in clinical practice.

Area of Science:

• Genetics
• Neurology
• Molecular Biology

Background:

• Mutations in the SCN1A gene are a primary cause of Dravet syndrome (DS), a severe form of early-onset epilepsy.
• SCN1A gene mutations are also implicated in other infantile epileptic encephalopathies, including genetic epilepsy with febrile seizures plus (GEFS+) and migrating partial seizures of infancy (MPSI).
• Accurate genetic diagnosis is vital for optimizing antiepileptic therapies and improving patient prognosis.

Purpose of the Study:

• To provide a practical reference guide for genetic testing of the SCN1A gene.
• To outline recommendations for SCN1A testing in suspected cases of DS and other early-onset epilepsies.
• To guide the interpretation of SCN1A test results, distinguishing between benign and pathogenic variations.

Main Methods:

• Conventional DNA sequencing of SCN1A coding regions.
• Analysis for genomic rearrangements within the 2q24 chromosomal region.
• Interpretation of results in the context of electroclinical syndromes, often with medical geneticist assistance.

Main Results:

• SCN1A testing is highly useful for confirming DS and guiding treatment, potentially improving seizure control and developmental outcomes.
• The clinical utility of SCN1A testing for GEFS+ is less established.
• Negative SCN1A test results do not exclude DS or other genetic epilepsies, as other genes may be involved.

Conclusions:

• Genetic confirmation of SCN1A mutations aids in precise diagnosis, personalized treatment, and genetic counseling for infantile epilepsies.
• Careful interpretation of SCN1A variants is essential, requiring correlation with clinical presentation and expert consultation.
• SCN1A testing is not recommended for phenotypes not clearly associated with SCN1A mutations.